



# BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017  
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com  
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)  
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date:12/02/2018

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
--	--

Sub: Approval of Un Audited Financial Result for the quarter and nine months ended on 31<sup>st</sup> December,2017 and Limited Review Report thereon .

Ref: Scripe Code: 524396; Sripe Id: BIOFILCHEM; ISIN: INE829A01014

Dear Sir/Madam

With reference to the above-mentioned subject, Board of the Directors of the Company in their meeting held on today, approved the Un Audited Financial Result for the quarter ended on 31<sup>st</sup> December 2017 and Limited Review Report thereon

Copy of audited financial result along with Limited Review Report is enclosed with this letter and copy of the same is also available on website of the Company. i.e www.biofilgroup.net

This is for your information and record.

Thanking you,

Yours Faithfully  
For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah  
Managing Director  
DIN :- 00028819





**Limited Review Report**


**The Board of Directors,  
M/S Biofil Chemicals And Pharmaceuticals Limited  
11/12, Sector E Sanwer Road  
Industrial Area  
Indore452015 -M.P.**

We have reviewed the accompanying statement of unaudited financial results (the "Statement") of Biofil Chemicals and Pharmaceuticals Limited ("the Company") for the quarter and Nine months ended 31<sup>st</sup> December 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, SEBI Circular CIF/CFD/CMD/15/2015 dated 30<sup>th</sup> November 2015, and CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Maheshwari & Gupta.  
Chartered Accountants  
FRN: 006179C**




**Sunil Maheshwari  
Partner  
M. No.403346**

**Date : 12.02.2018  
Place:-Indore**

**Un-Audited Financial Results of Quarter and Nine month Ended of Dec 2017**  
**M/s. Biofil Chemicals & Pharmaceuticals Limited**  
**11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)**  
CIN L24233MP1985PLC002709  
**UN- AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st Dec , 2017**

( Amount in Lakhs except EPS)

Statement of Standalone Unaudited Financial Results for the Quarter & Nine month ended 31st Dec 2017							
Particulars	Quarter Ended			Nine Month Ended		Audited for the year ended March 31 2017	
	3 months ended (31/12/2017)	Preceding 3 months ended (30/09/2017)	Corresponding 3 months ended in the previous year (31/12/2016)	Year to date figures for current period ended (31/12/2017)	Year to date figures for the previous year ended (31/12/2016)		
	Un- audited	Un- audited	Un- audited	Un- audited	Un-audited	Audited	
I Revenue from Operation	91.11	83.356	396.170	880.817	720.41	1347.739	
II Other Income	3.685	0.698	0.550	4.703	5.13	11.493	
III Total Revenue (I + II)	94.796	84.054	396.720	885.520	725.534	1359.232	
IV Expenses							
(a) Cost of materials consumed	13.149	12.204	29.323	38.876	60.193	90.414	
(b) Purchases of stock-in-trade	14.175	35.048	253.681	712.976	431.081	762.015	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.500	-4.200	-12.520	-5.900	-17.350	-1.323	
(d) Employee benefits expense	18.012	17.329	12.708	41.036	27.818	53.222	
(e) Finance Cost	3.768	3.865	3.750	11.382	11.250	16.358	
(f) Depreciation and Amortisation Expense	7.110	7.110	6.510	21.326	19.570	28.424	
(g) Other expenses	15.730	5.490	54.054	26.501	113.854	179.081	
Total expenses	72.444	76.846	347.505	846.197	646.415	1128.192	
V Profit (Loss) before exceptional items and tax (III-IV)	22.352	7.209	49.215	39.323	79.118	231.040	
VI Exceptional Items	0.000	0.000	0.000	0.000	0.000	0.000	
VII Profit (Loss) before tax (V - VI)	22.352	7.209	49.215	39.323	79.118	231.040	
VIII Tax expense:							
(1) Current tax	0.000	0.000	0.000	0.000	0.000	51.622	
(2) Deferred tax Credit/(Charge)	0.000	0.000	0.000	0.000	0.000	0.000	
IX Profit (Loss) for the period from continuing operation VII-VIII	22.352	7.209	49.215	39.323	79.118	179.417	
X Profit (Loss) for the period for dis-continued operation	0.000	0.000	0.000	0.000	0.000	0.000	
XI Tax expenses of discontinued operation	0.000	0.000	0.000	0.000	0.000	0.000	
XII Profit (Loss) for the period for dis-continued operation after tax (X-XI)	0.000	0.000	0.000	0.000	0.000	0.000	
XIII Profit (Loss) for the period (IX+XII)	22.352	7.209	49.215	39.323	79.118	179.417	
XIV Other Comprehensive Income							
A) (I) Items that will not be reclassified to Profit or Loss	0.000	0.000	0.000	0.000	0.000	0.000	
(II) Income Tax relating to items that will not be reclassified to Profit or Loss							
B) (I) Items that will be reclassified to Profit or Loss	0.000	0.000	0.000	0.000	0.000	0.000	
(II) Income Tax relating to items that will be reclassified to Profit or Loss				0.000			
c) Other Comprehensive Income (net of tax) 6a+ 6b)	0.000	0.000	0.000	0.000	0.000	0.000	
XV Total Comprehensive Income for the period (XIII + XIV)	22.352	7.209	49.215	39.323	79.118	179.417	
XVI Paid-Up equity share capital (face value of Rs 10/- each)	1627.380	1627.380	1627.380	1627.380	1627.380	1627.380	
XVII Other Equity excluding Revaluation Reserve as per balance Sheet			0.000			376.206	
XVIII Earnings per equity shares:							
(1) Basic (Rs)	0.137	0.044	0.302	0.242	0.486	1.102	
(2) Diluted (Rs)	0.137	0.044	0.302	0.242	0.486	1.102	



1. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2016.

2. The standalone unaudited financial results of Biofil Chemicals & Pharmaceuticals Ltd, ("the company" for the quarter ended December 31, 2017 were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on February 12, 2018.

3. The Limited Review of the financial Results of the Quarter ended 31st December 2017 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, has been carried out by the Statutory Auditors.

4. The Ind AS compliant corresponding figures for the quarter ended **December 31 2016**, have not been subject to review or audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

5. The Company has reported segment wise information as per Accounting Standard (AS-17). The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

1. Pharma Product
2. Chemicals Division
3. Plastic Division


6. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below.

Particulars	Quarter Ended	Nine Month Ended
	Dec 31 , 2016	Dec 31 , 2016
	Reviewed	Reviewed
	31.12.2016	31.12.2016
Total Income / Revenue From Operations	396.170	720.407
Net Profit for the period before tax (before Exceptional and/or Extraordinary items)	49.215	79.118
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	49.215	79.118
Net Profit for the period after tax	49.215	79.118
Total Comprehensive Income for the period {Comprising Profit for the period after Tax and Other	49.215	79.118
Paid up Equity Share Capital	1627.380	1627.380
Earning Per Share in Rs. (Per Share of Rs. 10 each, Basic &	0.302	0.486
Basic	0.302	0.486
Diluted		

7. The aforesaid audited financial Results will be uploaded on the Company's website [www.biofilgroup.net](http://www.biofilgroup.net) and will also be available on the websites of the Stock exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) for the benefit of shareholders and investors

Date : 12/02/2018  
Place : Indore

FOR AND ON BEHALF OF BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

  
RAMESH SHAH  
MANAGING DIRECTOR  
(DIN : 00028819)



**BIOFIL CHEMICALS & PHARMACEUTICALS LTD.**  
**CIN NO. L24233MP1985PLC002709**


Segmentwise Revenue, Results and Capital Employed for the period ended 31st Dec 2017

( Amount in Lakhs)

S.No.	Segment Revenue	Quarter Ended			Nine Month Ended		
		Dec 31 ,	Sept 30 ,	Dec 31 ,	Dec 31 ,	Dec 31 ,	March 31
		2017	2017	2016	2017	2016	2017
		Reviewed	Reviewed	Reviewed	Reviewed	Reviewed	Audited
		31.12.2017	30-09-2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
1	<b>Segment Revenue</b>						
	Pharma Unit	36.580	36.217	357.07	752.097	542.591	1,205.080
	Chemicals Division	54.531	47.140	38.10	125.876	97.846	139.077
	Plastic Division	0.000	0.000	1.00	2.844	1.001	1.281
	Other	3.685	0.698	0.55	4.703	84.096	13.794
	<b>Gross Turnover</b>	<b>94.796</b>	<b>84.054</b>	<b>396.714</b>	<b>885.520</b>	<b>725.534</b>	<b>1,359.232</b>
2	<b>Segment Results</b>						
	Pharma Unit	8.299	1.520	56.70	25.529	96.231	252.236
	Chemicals Division	21.553	13.192	0.31	33.455	8.118	(21.456)
	Plastic Division	(3.750)	(3.754)	(4.05)	(8.410)	(13.977)	(7.260)
	Other			0.000	0.000	0.000	19.839
	<b>Total Segment Profit Before Tax</b>	<b>26.102</b>	<b>10.958</b>	<b>52.962</b>	<b>50.575</b>	<b>90.372</b>	<b>243.358</b>
	Interest Income				0.000		2.686
	Interest Expenses	3.750	3.750	3.750	11.250	11.250	15.005
	Other Unallocable Income net of Expenditure						
	<b>Profit Before Tax</b>	<b>22.352</b>	<b>7.208</b>	<b>49.212</b>	<b>39.325</b>	<b>79.122</b>	<b>231.040</b>
	Provision for current tax	0.000	0.000				50.000
	Item Related Earlier Year	0.000	0.000				1.622
	<b>Profit After Tax</b>	<b>22.352</b>	<b>7.208</b>	<b>49.212</b>	<b>39.325</b>	<b>79.122</b>	<b>179.417</b>
3	<b>Capital Employed</b>						
	<b>Segment Assets (A)</b>						
	Pharma Division	1,417.266	1,814.497	1242.61	1,417.266	1,242.611	1,309.638
	Chemicals Division	854.118	836.440	772.24	854.118	772.238	802.498
	Plastic Division	67.877	67.877	78.34	67.877	78.344	71.902
	Other						0.000
	<b>Total (A)</b>	<b>2,339.261</b>	<b>2,718.814</b>	<b>2,093.193</b>	<b>2,339.261</b>	<b>2,093.193</b>	<b>2,184.039</b>
	<b>Segment Liabilities (B)</b>						
	Pharma Division	874.905	1,267.775	736.48	874.905	736.477	703.006
	Chemicals Division	40.467	55.950	20.90	40.467	20.896	66.529
	Plastic Division	152.238	148.864	148.59	152.238	148.588	144.850
	Other			-	0.000		
	<b>Total (B)</b>	<b>1,067.610</b>	<b>1,472.590</b>	<b>905.96</b>	<b>1,067.610</b>	<b>905.96</b>	<b>914.384</b>
	<b>Total Capital Employed</b>	<b>1,271.651</b>	<b>1,246.224</b>	<b>1,187.23</b>	<b>1,271.651</b>	<b>1,187.23</b>	<b>1,269.655</b>

DATE : 12-02-2018  
PLACE : INDORE

FOR AND ON BEHALF OF BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

  
**RAMESH SHAH**  
MANAGING DIRECTOR  
DIN: 00028819

